ABSTRACT
Qure.AI, a leading company in artificial intelligence (AI) applied to healthcare, has developed a suite of innovative solutions to revolutionize medical diagnosis and treatment. With a plethora of FDA-approved tools for clinical use, Qure.AI continually strives for innovation in integrating AI into healthcare systems. This article delves into the efficacy of Qure.AI's chest X-ray interpretation tool, "qXR," in medicine, drawing from a comprehensive review of clinical trials conducted by various institutions. Key applications of AI in healthcare include machine learning, deep learning, and natural language processing (NLP), all of which contribute to enhanced diagnostic accuracy, efficiency, and speed. Through the analysis of vast datasets, AI algorithms assist physicians in interpreting medical data and making informed decisions, thereby improving patient care outcomes. Illustrative examples highlight AI's impact on medical imaging, particularly in the diagnosis of conditions such as breast cancer, heart failure, and pulmonary nodules. AI can significantly reduce diagnostic errors and expedite the interpretation of medical images, leading to more timely interventions and treatments. Furthermore, AI-powered predictive analytics enable early detection of diseases and facilitate personalized treatment plans, thereby reducing healthcare costs and improving patient outcomes. The efficacy of AI in healthcare is underscored by its ability to complement traditional diagnostic methods, providing physicians with valuable insights and support in clinical decision-making. As AI continues to evolve, its role in patient care and medical research is poised to expand, promising further advancements in diagnostic accuracy and treatment efficacy.
Subject(s)
Humans , Female , Adult , Aortic Dissection/surgery , Aortic Dissection/diagnostic imaging , Costa RicaABSTRACT
In recent decades, improvements in breast cancer management have increased overall patient survival; however, many cancer therapies have been linked to an important risk of cardiovascular adverse events. Cardio-oncology has been proposed as an emerging specialty to coordinate preventive strategies that improve the cardiovascular health of oncologic patients. It employs the most suitable personalized multidisciplinary management approach for each patient to optimize their cardiovascular health and improve their survival and quality of life. Radiotherapy is an essential part of the therapeutic regimen in breast cancer patients but can also increase the risk of cardiovascular disease. Therefore, minimizing the negative impact of radiation therapy is an important challenge for radiotherapy oncologists and cardiologists specializing in this field. The aim of the present review is to update our knowledge about radiation-induced cardiotoxicity in breast cancer patients by undertaking a critical review of the relevant literature to determine risk prevention and control strategies currently available.
ABSTRACT
Resumen La Cardio-oncología es una nueva disciplina que busca enfocarse en el tamizaje, monitoreo y tratamiento de los pacientes con cáncer que presentan enfermedad cardiaca durante o después de recibir tratamiento. Esto debido a que el efecto cardiotóxico asociado a los quimioterapéuticos es ampliamente conocido y respaldado por abundantes estudios clínicos. Sin embargo, no es hasta épocas recientes que en Costa Rica se desarrollaron por primera vez Unidades Cardio-oncológicas, los cuales actualmente se ubican en diversos centros médicos de nuestro sistema de salud público. A continuación, se presenta un resumen de las manifestaciones clínicas de las diversas terapias oncológicas diferentes a las antraciclinas que tenemos a disposición en la Caja Costarricense del Seguro Social (CCSS).
Abstract Cardio-oncology is a new discipline that looks to focus on the screening, monitoring and treatment of patients withcancer that show up with heart disease during and after their treatment. This is due to the fact that the cardiotoxic effectsassociated to chemotherapeutics is widely known and backed up with abundant clinical trials. Nevertheless, it is not untilrecently that in Costa Rica the Cardio-oncologic Units were created for the first time, which now can be found in multiplemedical centers of our public health system. Up next, we present a summary of the clinical manifestations of the diversenon-anthracycline oncologic therapies that are available in the "Caja Costarricense del Seguro Social".
Subject(s)
Humans , Abnormalities, Radiation-Induced , Doxorubicin , Anthracyclines , Costa Rica , Cyclophosphamide , Drug Therapy , Cardiotoxicity , Trastuzumab , Sorafenib , Antibiotics, Antineoplastic , Antineoplastic AgentsABSTRACT
Resumen La cardiotoxicidad asociada al uso de quimioterapéuticos ha sido ampliamente corroborada a través de diversos estudios clínicos. En Costa Rica se han empezado a desarrollar Unidades Cardio-oncológicas en diversos centros médicos con el fin de detectar de manera precoz el efecto deletéreo cardiovascular asociado a los diferentes quimioterapéuticos. A con tinuación, se presenta un resumen de las manifestaciones clínicas cardiovasculares asociadas al uso de antraciclinas que tenemos a disposición en la Caja Costarricense del Seguro Social (CCSS)
Abstract Cardiotoxicity of anthracycline-type chemotherapeutics in the official list of medicines of the Caja Costarricense del Seguro Social Cardiotoxicity associated with the use of chemotherapy has been largely corroborated along multiple clinical trials. In Costa Rica, the development of Cardio-oncologic Units has begun recently in various medical centers with the purpose of achieving an early detection of the deleterious cardiovascular effect associated with different chemotherapeutics. This review consists of a summary of the clinical manifestations related to the use of anthracyclines available in the Costa Rican public health system.
Subject(s)
Humans , Anthracyclines , Costa Rica , Drug Therapy , Cardiotoxicity , Antineoplastic AgentsABSTRACT
Se presentan 17 casos de faringoamigdalitis, de los cuales 7 resultaron resistentes a macrólidos. Existe una tendencia mundial en el incremento de la resistencia del Streptococcus pyogenes con respecto a estos antibióticos. Este es un estudio pre-eliminar con el objetivo de sentar bases para iniciar una investigación prospectiva en el futuro.
Subject(s)
Humans , Male , Adolescent , Adult , Female , Child , Streptococcus pyogenes , Pharyngitis , Anti-Bacterial Agents/therapeutic use , Cephalosporins , Erythromycin , AmoxicillinABSTRACT
Se reporta el caso clínico de una paciente femenina de 37 años que presentó un cuadro de insuficiencia cardiaca secundario a un hipotiroidismo de fondo. Se ha vinculado manifestaciones cardiovasculares al hipotiroidismo por acción directa de las hormonas tiroideas al músculo cardíaco. Sin embargo, la insuficiencia cardiaca asociada a este tipo de patología es rara, con solo el reporte de un caso en la literatura revisada.
Subject(s)
Humans , Female , Adult , Cardiomyopathy, Dilated , Hypothyroidism , Heart Failure , Costa RicaABSTRACT
Se reporta el caso clínico de una paciente femenina de 43 años que presentó dos complicaciones secundarias al uso de propiltiuracilo: vasculitis y agronulocitosis. La vasculitis asociada con el tratamiento antitiroideo es una entidad clínica bien documentada, pero rara, y de un mecanismo patogénico no claro aún. Hay pocos casos reportados de asociación entre ingesta de propiltiouracilo, la aparición de anticuerpos anticitoplasmáticos antineutrófilos y vasculitis ANCA positiva. Este es probablemente uno de ellos. Descriptores: Propitiouracilo, vasculitis, autoanticuerpos citoplasmáticos anti-neutrófilo.
